vs

Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and REZOLVE AI PLC (RZLV). Click either name above to swap in a different company.

REZOLVE AI PLC is the larger business by last-quarter revenue ($1.2M vs $1.0M, roughly 1.2× Applied Therapeutics, Inc.). REZOLVE AI PLC runs the higher net margin — -1078.8% vs -1899.0%, a 820.2% gap on every dollar of revenue.

Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.

REZOLVE AI PLC is a UK-based technology firm developing AI-powered mobile engagement and instant transaction platforms. Its solutions let consumers complete purchases directly from audio, video, and print content, serving retail, consumer goods, and media clients across Europe, North America, and select APAC markets.

APLT vs RZLV — Head-to-Head

Bigger by revenue
RZLV
RZLV
1.2× larger
RZLV
$1.2M
$1.0M
APLT
Higher net margin
RZLV
RZLV
820.2% more per $
RZLV
-1078.8%
-1899.0%
APLT

Income Statement — Q3 FY2025 vs Q2 FY2025

Metric
APLT
APLT
RZLV
RZLV
Revenue
$1.0M
$1.2M
Net Profit
$-19.0M
$-13.0M
Gross Margin
Operating Margin
-1675.8%
-808.4%
Net Margin
-1899.0%
-1078.8%
Revenue YoY
719.7%
Net Profit YoY
72.3%
EPS (diluted)
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APLT
APLT
RZLV
RZLV
Q3 25
$1.0M
Q2 25
$0
$1.2M
Q1 25
$0
Q4 24
$-1.0K
Q2 24
$144.0K
Q1 24
$190.0K
Q4 23
$-667.0K
Q3 23
$0
Net Profit
APLT
APLT
RZLV
RZLV
Q3 25
$-19.0M
Q2 25
$-21.3M
$-13.0M
Q1 25
$-21.8M
Q4 24
$44.0M
Q2 24
$2.9M
Q1 24
$-83.9M
Q4 23
$-37.7M
Q3 23
$-42.4M
Operating Margin
APLT
APLT
RZLV
RZLV
Q3 25
-1675.8%
Q2 25
-808.4%
Q1 25
Q4 24
3302300.0%
Q2 24
-14194.4%
Q1 24
-11101.6%
Q4 23
3149.3%
Q3 23
Net Margin
APLT
APLT
RZLV
RZLV
Q3 25
-1899.0%
Q2 25
-1078.8%
Q1 25
Q4 24
-4400700.0%
Q2 24
2012.5%
Q1 24
-44177.9%
Q4 23
5649.0%
Q3 23
EPS (diluted)
APLT
APLT
RZLV
RZLV
Q3 25
$-0.13
Q2 25
$-0.15
Q1 25
$-0.15
Q4 24
$0.52
Q2 24
$-0.13
Q1 24
$-0.67
Q4 23
$-0.40
Q3 23
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APLT
APLT
RZLV
RZLV
Cash + ST InvestmentsLiquidity on hand
$11.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-561.0K
$-14.3M
Total Assets
$34.4M
$80.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APLT
APLT
RZLV
RZLV
Q3 25
$11.9M
Q2 25
$30.4M
Q1 25
$50.8M
Q4 24
$79.4M
Q2 24
$122.2M
Q1 24
$146.5M
Q4 23
$49.9M
Q3 23
$37.5M
Stockholders' Equity
APLT
APLT
RZLV
RZLV
Q3 25
$-561.0K
Q2 25
$17.4M
$-14.3M
Q1 25
$36.7M
Q4 24
$57.0M
Q2 24
$72.4M
Q1 24
$67.3M
Q4 23
$-17.1M
Q3 23
$-11.0M
Total Assets
APLT
APLT
RZLV
RZLV
Q3 25
$34.4M
Q2 25
$37.3M
$80.1M
Q1 25
$56.9M
Q4 24
$86.7M
Q2 24
$127.8M
Q1 24
$151.2M
Q4 23
$54.8M
Q3 23
$45.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APLT
APLT
RZLV
RZLV
Operating Cash FlowLast quarter
$-18.4M
$-4.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APLT
APLT
RZLV
RZLV
Q3 25
$-18.4M
Q2 25
$-20.3M
$-4.9M
Q1 25
$-28.6M
Q4 24
$-19.5M
Q2 24
$-22.6M
Q1 24
$-18.9M
Q4 23
$-17.0M
Q3 23
$-14.7M
Cash Conversion
APLT
APLT
RZLV
RZLV
Q3 25
Q2 25
Q1 25
Q4 24
-0.44×
Q2 24
-7.80×
Q1 24
Q4 23
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons